Literature DB >> 32269633

Imatinib therapy in acute myeloid leukemia with DEK-NUP214 and FIP1L1-PDGFRA rearrangement: A case report.

Yanping Yang1, Hai Lin1, Zhonghua Du1, Ruiping Hu1, Yang Tang1, Xinyue Liang1, Jingnan Sun1, Yehui Tan1.   

Abstract

The fusion product of FIP1-like-1 (FIP1L1) and platelet-derived growth factor receptor α (PDGFRA) gene rearrangement is a tyrosine kinase oncoprotein sensitive to imatinib. This gene rearrangement characterizes a novel clinico-biological class of myeloid and lymphoid neoplasms with eosinophilia and PDGFRA abnormalities. The DEK proto-oncogene (DEK) and nucleoporin 214 (NUP214) rearrangement is rare in patients with acute myeloid leukemia (AML); therefore, the coexistence of DEK-NUP214 and FIP1L1-PDGFRA rearrangements in patients with AML is extremely rare. The present study presents a rare relapse case of a patient with AML with DEK-NUP214 and FIP1L1-PDGFRA rearrangements, without marked eosinophilia in the peripheral blood or bone marrow. Low-dose imatinib monotherapy without intensive chemotherapy was used to achieve complete hematological remission.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  DEK proto-oncogene-nucleoporin 214 rearrangement; FIP1-like-1-platelet-derived growth factor receptor α rearrangement; acute myeloid leukemia; imatinib; therapy

Year:  2020        PMID： 32269633      PMCID： PMC7115152          DOI： 10.3892/ol.2020.11455

Source DB:  PubMed          Journal:  Oncol Lett        ISSN： 1792-1074            Impact factor:   2.967


  19 in total

Review 1.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Authors:  Peter Valent; Gerald J Gleich; Andreas Reiter; Florence Roufosse; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Karl Sotlar; Joseph H Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S Bochner; Jason Gotlib; Hans-Peter Horny; Hans-Uwe Simon; Amy D Klion
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

2.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

3.  Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.

Authors:  G Metzgeroth; C Walz; J Score; R Siebert; S Schnittger; C Haferlach; H Popp; T Haferlach; P Erben; J Mix; M C Müller; H Beneke; L Müller; F Del Valle; W E Aulitzky; G Wittkowsky; N Schmitz; C Schulte; K Müller-Hermelink; E Hodges; S J Whittaker; F Diecker; H Döhner; P Schuld; R Hehlmann; A Hochhaus; N C P Cross; A Reiter
Journal:  Leukemia       Date:  2007-03-22       Impact factor: 11.528

4.  Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis.

Authors:  K Ishiyama; A Takami; Y Kanda; S Nakao; M Hidaka; T Maeda; T Naoe; S Taniguchi; K Kawa; T Nagamura; Y Atsuta; H Sakamaki
Journal:  Leukemia       Date:  2011-08-26       Impact factor: 11.528

5.  PDGFRA rearrangement leading to hyper-eosinophilia, T-lymphoblastic lymphoma, myeloproliferative neoplasm and precursor B-cell acute lymphoblastic leukemia.

Authors:  Q Huang; D S Snyder; P Chu; K K Gaal; K L Chang; L M Weiss
Journal:  Leukemia       Date:  2010-11-23       Impact factor: 11.528

Review 6.  Myeloid neoplasms with eosinophilia.

Authors:  Andreas Reiter; Jason Gotlib
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

Review 7.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

8.  The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Authors:  Michele Baccarani; Daniela Cilloni; Michela Rondoni; Emanuela Ottaviani; Francesca Messa; Serena Merante; Mario Tiribelli; Francesco Buccisano; Nicoletta Testoni; Enrico Gottardi; Antonio de Vivo; Emilia Giugliano; Ilaria Iacobucci; Stefania Paolini; Simona Soverini; Gianantonio Rosti; Francesca Rancati; Cinzia Astolfi; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli
Journal:  Haematologica       Date:  2007-08-01       Impact factor: 9.941

9.  Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.

Authors:  Heng Joo Ng; Daryl C L Tan; Richard C Yiu; Gee Fung How
Journal:  Leuk Res       Date:  2007-06-04       Impact factor: 3.156

10.  Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.

Authors:  Carl Sandén; Malin Ageberg; Jessica Petersson; Andreas Lennartsson; Urban Gullberg
Journal:  BMC Cancer       Date:  2013-09-27       Impact factor: 4.430
View more
  1 in total

1.  Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia.

Authors:  Genki Yamato; Tomoko Kawai; Norio Shiba; Junji Ikeda; Yusuke Hara; Kentaro Ohki; Shin-Ichi Tsujimoto; Taeko Kaburagi; Kenichi Yoshida; Yuichi Shiraishi; Satoru Miyano; Nobutaka Kiyokawa; Daisuke Tomizawa; Akira Shimada; Manabu Sotomatsu; Hirokazu Arakawa; Souichi Adachi; Takashi Taga; Keizo Horibe; Seishi Ogawa; Kenichiro Hata; Yasuhide Hayashi
Journal:  Blood Adv       Date:  2022-06-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.